CNBC’s Ashley Capoot recently tested out a metabolic health platform from the startup Signos, wearing a small continuous glucose monitor (CGM) on her arm. This platform offers a subscription service that aims to help users lose weight by tracking their blood sugar levels. The subscription price varies depending on the plan chosen, with a one-month plan starting at $449. However, competing companies such as Dexcom are also entering the market with similar products.
Capoot shared her firsthand experience with Signos’ platform, which uses CGMs and an artificial intelligence-powered app to provide personalized insights into how daily habits like diet, exercise, stress, and sleep affect blood sugar levels. Glucose spikes, which occur after eating, can lead to health issues over time if not managed properly. Signos aims to help users stabilize their glucose levels to improve their metabolism, lose weight, and reduce the risk of chronic diseases.
To get started with Signos, Capoot took a questionnaire and received approval for a CGM prescription. The kit included instructions, CGMs, alcohol wipes, and athletic patches for application. Capoot found the setup process easy and painless, with the CGM being small and discreet once applied. The Signos app guided her through the process and provided educational resources to help her understand and manage her blood sugar levels.
Throughout her trial, Capoot found the CGM to be comfortable and easy to wear, forgetting about it at times. The Signos platform helped her interpret her glucose data and guided her in maintaining her optimal glucose range. Activities and articles in the app deepened her understanding of her blood sugar levels and how daily choices can impact them.
Overall, Capoot’s experience with Signos’ platform was positive, with the company’s focus on personalized insights and support from registered dieticians setting it apart in the growing market of consumer-facing CGM systems.